When was DotLab founded?

DotLab was founded in 2016 and raised its 1st funding round 3 years after it was founded.

Where is DotLab located?

DotLab is headquartered in Branford, United States. It is registered at 780 East Main Street, Suite 1 Branford, CT 06405.

Who is the current CEO of DotLab?

Heather Bowerman of DotLab. They have also founded 1 company.

How many employees does DotLab have?

As of Oct 31, 2026, the latest employee count at DotLab is 8.

Is DotLab a funded company?

DotLab is a funded company, having raised a total of $10M across 2 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on May 01, 2019.

When was the latest funding round of DotLab?

DotLab's latest funding was a $***** Series A round on Jul 01, 2019, with participation from 4 investors.

Where does DotLab rank among its competitors?

DotLab ranks 6th amongst 97 active competitors, of which 33 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Hera Biotech, which secured $250K in Sep, 2025.

Who are the top competitors of DotLab?

DotLab's top competitors include OncoCyte, Codiak BioSciences and Mursla. Among them, Hera Biotech secured the most recent funding round in September, 2025.

DotLab - 2026 Company Profile, Team, Funding & Competitors

DotLab is a series A company based in Branford (United States), founded in 2016 by Heather Bowerman. It operates as a Provider of a molecular diagnostic testing tool for endometriosis in women. DotLab has raised $10M in funding from CooperSurgical. The company has 97 active competitors, including 33 funded and 12 that have exited. Its top competitors include companies like OncoCyte, Codiak BioSciences and Mursla.

Company Details

Provider of a molecular diagnostic testing tool for endometriosis in women. The company has developed a product DotEndo that works by measuring biomarkers in the blood in order to identify endometriosis in women. The company's technology is a saliva-based liquid biopsy that detects specific miRNAs in the sample to diagnose endometriosis early in patients who would otherwise need to undergo laparoscopic surgery for diagnosis. The test is prescribed by the physician who can collect the saliva sample and send it to the company's CLIA and CAP-certified lab for testing.

Website: www.dotlab.com/
Social
Phone Number: +1 **********
Registered Address: 780 East Main Street, Suite 1 Branford, CT 06405

Key Metrics

Founded Year

2016

Location

Branford, United States

Stage

Series A

Total Funding

$10M in 2 rounds

Latest Funding Round

Series A, Jul 01, 2019, $*****

Investors

CooperSurgical & 7 more

Ranked

6^th among 97 active competitors

Employee Count

8 as on Oct 31, 2026

Similar Companies

OncoCyte & 73 more

View DotLab's full profile

DotLab is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
DOT LABORATORIES, INC. CIN: 81-2673630 , United States, Active	May 15, 2016	-	11 (As on Dec 31, 2021)	-

DotLab has raised a total funding of $10M over 2 rounds. Its first funding round was on May 01, 2019. Its latest funding round was a Series A round on Jul 01, 2019 for $*****. 4 investors participated in its latest round. DotLab has 8 institutional investors.

Here is the list of recent funding rounds of DotLab:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 01, 2019	2417723	Series A	7885026	7202687	3483168	7863838
May 01, 2019	9298658	Grant (prize money)	7771162	7608962	1445963	HHS

Access funding benchmarks and valuations. Sign up today!

View details of DotLab's funding rounds and investors

The founders of DotLab is Heather Bowerman. Heather Bowerman is the CEO of DotLab.

Here are the details of DotLab's key team members:

Heather Bowerman: Founder & CEO of DotLab.
Contact Info: 1 email address

View details of DotLab's Founder profiles and Board Members

DotLab's employee count trend

DotLab has 8 employees as of Oct 26. Here is DotLab's employee count trend over the years:

Uncover DotLab's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of DotLab include OncoCyte, Codiak BioSciences and Mursla. Here is the list of Top 10 competitors of DotLab, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	OncoCyte 2009, Irvine (United States), Public	Developer of non-invasive diagnostic tests solutions for the treatment of cancer	$15.3M	Geode Capital, Connor, Clark & Lunn Financial Group ... & 5 others	66/100
2nd	Codiak BioSciences 2015, Cambridge (United States), Public	Developer of exosome-based drugs and diagnostics for cancer treatment	$168M	Arch Venture Partners, Flagship Pioneering ... & 10 others	57/100
3rd	Mursla 2017, London (United Kingdom), Seed	Provider of diagnostic device for cancer detection	$547K	Future Fund, TA Ventures & 26 others	55/100
4th	Miroculus 2014, San Francisco (United States), Acquired	Developer of MicroRNA profiling platform to detect genes in the sample	$48.4M	Cota Capital, Nazca & 11 others	50/100
5th	Hera Biotech 2020, San Antonio (United States), Seed	Developer of diagnostic test kit for endometriosis	$3.21M	Birmingham Angels, Coyote Ventures & 6 others	49/100
6th	DotLab 2016, Branford (United States), Series A	Provider of a molecular diagnostic testing tool for endometriosis in women	$10M	Wilson Sonsini Goodrich & Rosati, Luxor Capital Group ... & 6 others	46/100
7th	Pacific Edge 2011, Dunedin (New Zealand), Public	-	$1.75M	-	49/100
8th	Mirvie 2019, San Francisco (United States), Series B	Provider of non-invasive diagnostic tests for pregnant women	$114M	Decheng Capital, Khosla Ventures & 10 others	47/100
9th	DiamiR 2009, Monmouth Junction (United States), Funding Raised	Developer of minimally invasive diagnostic tests	-	NIA, HHS	45/100
10th	Augurex 2006, Vancouver (Canada), Seed	Developer of diagnostic tests to detect autoimmune and chronic diseases	$978K	WUTIF Capital	45/100